Effects of homocysteine on L-arginine transport and nitric oxide formation in human platelets

European Journal of Clinical Investigation

Volumn 33, Issue 8, 2003, Pages 713-719

  Leoncini, Giuliana ^a   Pascale, R ^a   Signorello, M G ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Ca2+; Homocysteine; Human platelets; L arginine transport; Nitric oxide

Indexed keywords

AMINO ACID; ARGININE; CALCIUM ION; HOMOCYSTEINE; NITRATE; NITRIC OXIDE; NITRITE;

AMINO ACID TRANSPORT; ARTICLE; ATHEROSCLEROSIS; CELL FREE SYSTEM; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

ARGININE; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; CALCIUM; CELL-FREE SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLMALEIMIDE; HOMOCYSTEINE; HUMANS; LEUCINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLATELET AGGREGATION;

EID: 0042666891     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01203.x     Document Type: Article

References (40)

1. de Jong SC, van den Berg M, Rauwerda JA, Stehouwer CD. Hyperhomocysteinemia and atherothrombotic disease. Semin Thromb Hemost 1998;24:381-5.
2. Domagala TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinaemia. J Cardiovasc Risk 1998;5:239-47.
3. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998;44:1833-43.
4. Eikelboom JW, Lonn E, Genest J, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75.
5. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemost 1999;81:165-76.
6. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD. Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001;85:153-8.
7. Upchurch GR Jr, Welch GN, Fabian AJ, Freedman JE, Johnson JL, Keaney JF Jr et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997;272:17012-7.
8. Mutus B, Rabini RA, Staffolani R, Ricciotti R, Fumelli P, Moretti N et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001;44:979-82.
9. Signorello MG, Pascale R, Leoncini G. Effect of homocysteine on arachidonic acid release in human platelets. Eur J Clin Invest 2002;32:279-84.
10. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999;43:580-94.
11. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993;91:308-18.
12. Dardik R, Varon D, Tamarin I, Zivelin A, Salomon O, Shenkman B et al. Homocysteine and oxidized low density lipoprotein enhanced platelet adhesion to endothelial cells under flow conditions: distinct mechanisms of thrombogenic modulation. Thromb Haemost 2000;83:338-44.
13. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 1999;281:2113-8.
14. Davi G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P et al. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 2001;104:1124-8.
15. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997;90:1-11.
16. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992;89:10193-7.
17. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991;88:1906-14.
18. Palareti G, Coccheri S. Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyridoxine-folate regimen. Haemostasis 1989;19:24-8.
19. Nishinaga M, Ozawa T, Shimada K. Homocysteine, a thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcine aortic endothelial cells. J Clin Invest 1993;92:1381-6.
20. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells. Blood 1992;79:2930-6.
21. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 1993;91:2873-9.
22. Leoncini G, Maresca M, Buzzi E, Piana A, Armani U. Platelets of patients affected with Essential Thrombocythemia are abnormal in plasma membrane and adenine nucleotide content. Eur J Haematol 1990;44:116-20.
23. 2+ in human platelets. FEBS Lett 1999;461:43-6.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin phenol reagent. J Biol Chem 1951;193:265-75.
25. Rotondo S, Evangelista V, Manarini S, De Gaetano G, Cerletti C. Different requirement of intracellular calcium and protein kinase C for arachidonic acid release and serotonin secretion in cathepsin G-activated platelets. Thromb Haemost 1997;78:919-25.
26. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
27. Signorello MG, Pascale R, Leoncini G. Transport of 1-arginine and nitric oxide formation in human platelets. Eur J Biochem, 2003;270:2005-12.
28. Deves R, Angelo S, Chavez P. N-ethylmaleimide discriminates between two lysine transport systems in human erythrocytes. J Physiol 1993;468:753-66.
29. Radomski MW, Palmer RM, Moncada S. An 1-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-7.
30. Palmer RM, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989;158:348-52.
31. Muruganandam A, Mutus B. Isolation of nitric oxide synthase from human platelets. Biochim Biophys Acta 1994;1200:1-6.
32. Closs EI, Scheld JS, Sharafi M, Forstermann U. Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol 2000;57:68-74.
33. Jin L, Abou-Mohamed G, Caldwell RB, Caldwell RW. Endothelial cell dysfunction in a model of oxidative stress. Med Sci Monit 2001;7:585-91.
34. Leoncini G, Pascale R, Signorello MG. Modulation of 1-arginine transport and nitric oxide production by gabexate mesylate. Biochem Pharmacol 2002;64:277-83.
35. Ogonowski AA, Kaesemeyer WH, Jin L, Ganapathy V, Leibach FH, Caldwell RW. Effects of NO donors and synthase agonists on endothelial cell uptake of 1-arg and superoxide production. Am J Physiol Cell Physiol 2000;278:C136-43.
36. Cynober LA. Plasma amino acid levels with a note on membrane transport: characteristics, regulation, and metabolic significance. Nutrition 2002;18:761-6.
37. Deves R, Boyd CA. Transporters for cationic amino acids in animal cells. Discovery, Structure, Function Physiol Rev 1998;78:487-545.
38. Mujumdar VS, Hayden MR, Tyagi SC. Homocyst(e)ine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000;183:28-36.
39. Authi KS. In: Authi, KS, Watson, SP, Kakkor, VV, editors. Mechanism of Platelet Activation and Control. NewYork: Plenum Press;1993.p.83-104.
40. Mayer B, John M, Heinzel B, Werner ER, Wachter H, Schultz G et al. Brain nitric oxide synthase is a biopterin- and flavin-containing multi-functional oxido-reductase. FEBS Lett 1991;288:187-91.